Cited 0 time in
Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Jung Hun | - |
| dc.contributor.author | Kwak, Yeonui | - |
| dc.contributor.author | Song, Chiman | - |
| dc.contributor.author | Roh, Eun Joo | - |
| dc.contributor.author | Oh, Chang-Hyun | - |
| dc.contributor.author | Lee, So Ha | - |
| dc.contributor.author | Sim, Taebo | - |
| dc.contributor.author | Choi, Jung Hoon | - |
| dc.contributor.author | Yoo, Kyung Ho | - |
| dc.date.accessioned | 2024-01-10T03:37:19Z | - |
| dc.date.available | 2024-01-10T03:37:19Z | - |
| dc.date.issued | 2016-10 | - |
| dc.identifier.issn | 0960-894X | - |
| dc.identifier.issn | 1464-3405 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/194051 | - |
| dc.description.abstract | A novel series of arylurea and arylamide derivatives 1a-z, 2a-d having aminoquinazoline scaffold was designed and synthesized. Their in vitro antiproliferative activities against RT112 bladder cancer cell line and inhibitory activities against FGFR3 kinase were tested. Most compounds showed good antiproliferative activities against RT112 bladder cancer cell line, and arylurea compounds 1a-z were more potent than arylamide compounds 2a-d. Among them, eight compounds 1a, 1d-g, 1l, 1y, and 1z showed potent activities with GI(50) values below submicromolar range. Especially, arylurea compounds 1d and 1g possessing 2,3-dimethyl and 3,4-dimethyl moieties exhibited superior or similar antiproliferative activity (GI(50) = 8.8 nM and 30.2 nM, respectively) to AZD4547 (GI(50) = 29.2 nM) as a reference standard. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Pergamon Press Ltd. | - |
| dc.title | Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1016/j.bmcl.2016.08.076 | - |
| dc.identifier.scopusid | 2-s2.0-84988911818 | - |
| dc.identifier.wosid | 000385498500045 | - |
| dc.identifier.bibliographicCitation | Bioorganic & Medicinal Chemistry Letters, v.26, no.20, pp 5082 - 5086 | - |
| dc.citation.title | Bioorganic & Medicinal Chemistry Letters | - |
| dc.citation.volume | 26 | - |
| dc.citation.number | 20 | - |
| dc.citation.startPage | 5082 | - |
| dc.citation.endPage | 5086 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
| dc.subject.keywordPlus | GROWTH-FACTOR RECEPTORS | - |
| dc.subject.keywordPlus | SELECTIVE INHIBITOR | - |
| dc.subject.keywordPlus | FGFR1 INHIBITORS | - |
| dc.subject.keywordPlus | POTENT | - |
| dc.subject.keywordPlus | DISCOVERY | - |
| dc.subject.keywordPlus | DESIGN | - |
| dc.subject.keywordAuthor | Arylaminoquinazolinylureas | - |
| dc.subject.keywordAuthor | Arylaminoquinazolinylamides | - |
| dc.subject.keywordAuthor | Antiproliferative activity | - |
| dc.subject.keywordAuthor | Bladder cancer cell line | - |
| dc.subject.keywordAuthor | Enzymatic activity | - |
| dc.subject.keywordAuthor | FGFR3 | - |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0960894X16309088?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
